News & Media
TheraCell Announces Royalty Milestone From Licensing
TheraCell, Inc. a leading allograft solution company, today announced that as of September 30, 2020 its royalty income from the licensees of its base demineralized bone fiber technology had surpassed a $1.0M annual run rate. With consistent quarter over quarter growth, this achievement represents a 55% increase over the annual run rate observed at the same time last year.
TheraCell Announces First Surgical Use Of TheraFuze DBF® Fiber Anchor™ For Pedicle Screw Augmentation
TheraCell, Inc. a leading bone technology company today announced that it has completed the first three spine surgical cases using the world's first ever demineralized bone fiber screw anchor. This unique product acts much like a drywall anchor that provides immediate improvement in screw fixation in primary and revision cases.
TheraCell Announces Delivery of Over 12,000 Of Its Licensed Bone Grafts
TheraCell, Inc. a leading bone solution company today announced that over 12,000 of its novel demineralized bone fiber products have been delivered - primarily for use in spinal fusions. With steady double-digit quarter over quarter growth generated by its licensees and OEM partners, its products have reached an annual end customer sales rate of over $15M.
TheraCell’s 2nd Generation TheraFuze DBF® portfolio of demineralized bone fiber solutions includes the broadest range of demineralized bone fiber solutions available today - manufactured exclusively for TheraCell by Pinnacle Tissue Transplant, Phoenix, AZ.
Additionally, TheraCell has partnerships with AlloSource, Nuvasive and Australian Biotechnologies who sell products utilizing TheraCell technology under license.
TheraCell believes strongly in the power of partnerships to progress science and product development and seeks mutually rewarding partnerships. We currently have non exclusive partnerships with companies who are evaluating the synergy between TheraCell’s DBF™ fibers and growth factors and autologous cell therapy products.
Contact us to discuss partnering your technology, or any other partnership opportunities.
Bone fiber technology for veterinary markets
TheraCell-VET is the veterinary products division of TheraCell. The company is dedicated to bringing the advantages of TheraCell’s demineralized bone fiber technology and product pipeline to the veterinary market. Our flagship product VET Fiber Matrix™ is the only veterinary bone grafting product that offers osteoinductivity and osteoconductivity in a natural, additive free product.
DermOQ, Inc. is a skincare brand that brings the latest advances in oxygenated skincare from the world-renowned scientists who are revolutionizing tissue repair with oxygen. DermOQ, Inc. has developed a proprietary MaxOx™ oxygen delivery system for supplying molecular oxygen and other active nutrients into the skin to keep it in its most dynamic and alive state. Our patent pending innovative oxygen delivery systems use highly soluble oxygen compounds enhanced with molecular oxygen to penetrate and replenish the skin, delaying and reversing the effects of aging. Founded in 2017, the brand is headquartered in Los Angeles and maintains offices, laboratories and production facilities in the Boston area. www.dermoq.com. MaxOx™ is a trademark of DermOQ.